TCF3 and acute lymphoblastic leukemia: Traditionally high-risk (HR) features, TCF3-PBX1, iAMP21, and KMT2A-rearranged ALL, were observed in 8.3% (n=43/521), 1.1% (n=11/99), and 2.2% (n=11/503) of patients respectively (Table 2).